EP.png
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma
June 11, 2024 02:00 ET | Essential Pharma
Essential Pharma reaches agreement with AGC Biologics for late phase clinical manufacturing of its immunotherapy candidate for the treatment of high-risk neuroblastoma Egham, UK and Copenhagen,...
AGC Biologics Honore
AGC Biologics Honored for Innovations in Cell Line Development
October 13, 2022 08:37 ET | AGC Biologics
Seattle, Oct. 13, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced it has been named a 2022...
AGC Biologics and Ev
AGC Biologics and Evax Partner to Advance Promising Equine Allergy Vaccine Candidate
September 07, 2022 17:00 ET | AGC Biologics
Seattle, Sept. 07, 2022 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), today announced a new partnership with Evax,...
AGC Biologics Announces the Groundbreaking of its New Facility at its Copenhagen, Denmark Site
August 20, 2021 13:39 ET | AGC Biologics
COPENHAGEN, Aug. 20, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announces the groundbreaking of its new...
AGC Biologics Appoin
AGC Biologics Appoints Tony Fraij as the new General Manager/Site Head of the Longmont, Colorado Site
August 09, 2021 13:00 ET | AGC Biologics
LONGMONT, Aug. 09, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new leadership appointment...
AGC Biologics Acquires Commercial Facility, Expanding Cell & Gene Therapy Global Service Offerings
August 05, 2021 12:00 ET | AGC Biologics
Seattle, Aug. 05, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the finalization of the purchase of...
AGC Biologics Appoin
AGC Biologics Appoints Kevin Ingham as the new General Manager/Site Head of their Seattle, Washington Site
August 02, 2021 14:00 ET | AGC Biologics
Seattle, Aug. 02, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced a new appointment to oversee...
AGC Biologics Enters Agreement to Acquire Facility in Longmont, CO, Eyeing to Significantly Expand Their Cell and Gene Therapy Capabilities and Offerings
July 01, 2021 12:00 ET | AGC Biologics
Seattle, July 01, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global biopharmaceutical Contract Development and Manufacturing Organization (CDMO), announced the signing of a purchase agreement...
Chemomab Therapeutic
Chemomab Therapeutics and AGC Biologics Expand Partnership to Manufacture CM-101 for Phase II/III
June 23, 2021 08:30 ET | AGC Biologics
TEL AVIV, Israel and SEATTLE, Wash., June 23, 2021 (GLOBE NEWSWIRE) -- Chemomab Therapeutics, Ltd. (NASDAQ: CMMB), a clinical-stage biotech company focused on the discovery and development of...
AGC Biologics’ Heide
AGC Biologics’ Heidelberg Facility to Further Supply Plasmid DNA for COVID-19 Vaccine
June 07, 2021 10:06 ET | AGC Biologics
Seattle, June 07, 2021 (GLOBE NEWSWIRE) -- AGC Biologics, a leading global Biopharmaceutical Contract Development and Manufacturing Organization (CDMO), has announced its partnership with BioNTech...